Chiain “James” Lin, a leading biomedical researcher and innovator, has been named the first executive director of the Institute for Convergent Bioscience and Technology at Indiana University Indianapolis.
The institute is part of a $250 million investment from the university to advance scientific discoveries aimed at treating and curing disease and improving human health.
“Indiana University's commitment to biosciences is leading to innovative discoveries and life-changing health outcomes for Hoosiers across the state,” said IU President Pamela Whitten. “Led by James Lin, the Convergent Bioscience and Technology Institute will expand IU's role in central Indiana's thriving bioscience community and accelerate the significant impact of IU's innovative research. I will.”
Lin will also serve as professor of biomedical engineering in the Rudy School of Informatics, Computing, and Engineering, and will assume his position on August 26.
“I am pleased to welcome Dr. James Lin as executive director of the Institute for Convergent Bioscience and Technology,” said IU Indianapolis President Latha Ramchand. “An award-winning scientist, Dr. Lin brings extensive experience in orthopedic medicine, translational tissue engineering research, and entrepreneurial success, all of which have led him to the Polis makes him the ideal leader for the Institute to accelerate the impact of research and development. ”
Lin will lead Convergent Bioscience, which advances interdisciplinary bioscience and technology research and collaboration within IU, including collaborations with IU School of Medicine researchers and industry partners such as the Indiana Bioscience Institute and BioCrossroads. Provides a comprehensive vision of the Institute of Technology. Under his direction, the company will pursue innovative discoveries such as wearable and implantable medical devices and sensors, and AI-enabled drug discovery and discovery.
“I am honored to embark on this transformative journey at a historic crossroads, becoming the first executive director of the Convergent Bioscience and Technology Institute and joining the Rudy School of Informatics, Computing, and Engineering at IU Indianapolis. We’re excited to get on board,” Lin said. “I look forward to working with faculty and university leaders to establish the Institute as a key element in enhancing research creativity and productivity. Our vision is to provide cutting-edge bioscience and To lead at the intersection of technology and drive innovation that has a positive impact on society.”
In line with the goals of the IU 2030 Strategic Plan, the Institute strives to deliver IU health and science innovations from the clinic to the bedside, and promotes inventions, discoveries and innovations, industry partnerships, and IU disclosures and licensing. We will also contribute to the expansion of・Launched a start-up company.
“Over the next five years, the Convergent Bioscience and Technology Institute will focus on fostering interdisciplinary collaboration, accelerating research translation, and developing talent to address critical global challenges.” he said. “Central to our strategy is to convene a respected advisory board comprised of leaders from academia, industry and government. We will integrate diverse expertise and leverage emerging technologies such as artificial intelligence and machine learning. By leveraging our capabilities, we will work together to deliver breakthrough innovations, secure strategic partnerships, and chart a course that ensures the Institute's impact is far-reaching.”
Lin is currently at the University of Cincinnati, where his research focuses on developing new innovations for tissue engineering and regenerative medicine, with results that significantly advance current standards in the treatment of musculoskeletal diseases. improved. His research in biofabrication led to numerous inventions and applications in the repair of birth defects and skeletal reconstruction. He collaborates on collaborative research projects with key partners in the greater Cincinnati region, including Cincinnati Children's Hospital and Procter & Gamble.
An entrepreneur, Lin has co-founded multiple startups, including one recently acquired by DePuy Synthes, a subsidiary of Johnson & Johnson. His latest startup, his biopharmaceutical company called Amplicore Inc., specializes in developing new injectables to treat damaged and degenerated skeletal soft tissue.
“We are excited to have James Lin lead the Institute for Convergent Bioscience and Technology at IU Indianapolis, where his leadership will continue to advance bioscience discoveries in central Indiana. It will help expand our role in advancing the University of California,” said Fedora Corso, IU vice provost for research. Dean of Research at IU Indianapolis. “His innovative thinking and collaboration with industry partners will support the growth of transformative research that improves Hoosier lives and economies, while also establishing IU as one of the nation's leading urban research universities.” It will also help.”
Lin received her Ph.D. He earned his master's degree at the University of Michigan, where he began his academic career as an assistant professor of neurosurgery and served as founding director of the Spine Research Institute. He received his bachelor's degree from National Taiwan University.
